TScan Therapeutics (NASDAQ:TCRX) Earns Outperform Rating from Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reiterated by Wedbush in a research report issued on Wednesday,RTT News reports. They presently have a $7.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 236.54% from the stock’s previous close.

Several other brokerages have also recently weighed in on TCRX. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Needham & Company LLC decreased their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday.

TScan Therapeutics Trading Up 8.3 %

NASDAQ TCRX opened at $2.08 on Wednesday. TScan Therapeutics has a 52 week low of $1.82 and a 52 week high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The stock’s 50 day moving average price is $2.43 and its two-hundred day moving average price is $4.04. The stock has a market capitalization of $111.01 million, a price-to-earnings ratio of -1.96 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million during the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TCRX. China Universal Asset Management Co. Ltd. bought a new stake in shares of TScan Therapeutics in the 4th quarter valued at about $32,000. Prudential Financial Inc. bought a new stake in TScan Therapeutics in the fourth quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new stake in shares of TScan Therapeutics in the fourth quarter valued at approximately $40,000. Squarepoint Ops LLC bought a new position in shares of TScan Therapeutics during the 4th quarter worth approximately $59,000. Finally, Wells Fargo & Company MN increased its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after acquiring an additional 5,694 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.